Hikma Pharmaceuticals Plc Holding(s) in Company (9963O)
25 August 2017 - 5:41PM
UK Regulatory
TIDMHIK
RNS Number : 9963O
Hikma Pharmaceuticals Plc
25 August 2017
TR-1: Standard form for notification of major holdings
LONDON, 25 August 2017 - Hikma Pharmaceuticals PLC ("Hikma")
(LSE: HIK) (DIFX: HIK) (LEI: 549300BNS685UXH4JI75), the
fast-growing multinational pharmaceuticals group, announces as
follows:
NOTIFICATION OF MAJOR HOLDINGS
1. Identity of the issuer or Hikma Pharmaceuticals PLC
the underlying issuer
of existing shares to which
voting rights are
attached: (ii)
---------------------------------------------------------- ---------------------------
2. Reason for the notification (please tick the appropriate
box or boxes):
---------------------------------------------------------------------------------------
An acquisition or disposal of voting rights YES
----------------------------------------------------------- --------------------------
An acquisition or disposal of qualifying financial
instruments which may result in the acquisition
of shares already issued to which voting rights
are attached
----------------------------------------------------------- --------------------------
An acquisition or disposal of instruments with
similar economic effect to qualifying financial
instruments
----------------------------------------------------------- --------------------------
An event changing the breakdown of voting rights
----------------------------------------------------------- --------------------------
Other (please
specify):
--------------------------------------------------------- --------------------------
3. Full name of person(s) Vanguard Health Care Fund
subject to the
notification obligation:
(iii)
---------------------------------------------------------- ---------------------------
4. Full name of shareholder(s)
(if different from 3.):(iv)
---------------------------------------------------------- ---------------------------
5. Date of the transaction 22 August 2017
and date on
which the threshold is
crossed or
reached: (v)
---------------------------------------------------------- ---------------------------
6. Date on which issuer 24 August 2017
notified:
---------------------------------------------------------- ---------------------------
7. Threshold(s) that is/are
crossed or
reached: (vi, vii) 3%
---------------------------------------------------------- ---------------------------
8. Notified details:
--------------------------------------------------------------------------------------------------------------------------
A: Voting rights attached to shares (viii, ix)
--------------------------------------------------------------------------------------------------------------------------
Class/type Situation previous Resulting situation after the
of to the triggering triggering transaction
shares transaction
if possible
using
the ISIN
CODE
---------------- -------------------------------- ----------------------------------------------------------------------
Number Number Number Number of % of voting
of of of shares voting rights (x)
Shares Voting rights
Rights
-------------- --------------- --------------- ----------------- -------------------------- -----------------------
Direct Direct (xi) Indirect Direct Indirect
(xii)
-------------- ----------- ----------- ----------------- ------------- ----------- ---------- -----------
GB00B0LCW083 7,186,729 7,186,729 7,284,981 7,284,981 3.03%
--------------- --------------- ----------------- ------------- ----------- ---------- -----------
B: Qualifying Financial Instruments
--------------------------------------------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
--------------------------------------------------------------------------------------------------------------------------
Type of financial Expiration Exercise/ Number of voting % of voting
instrument date Conversion rights that rights
(xiii) Period (xiv) may be
acquired if
the
instrument
is
exercised/
converted.
------------------ --------------- ------------------------------ ------------------------------ ---------------------
N/A
------------------ --------------- ------------------------------ ------------------------------ ---------------------
C: Financial Instruments with similar economic effect
to Qualifying Financial Instruments (xv, xvi)
--------------------------------------------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
--------------------------------------------------------------------------------------------------------------------------
Type of Exercise Expiration Exercise/ Number of voting % of voting
financial price date Conversion rights instrument rights (xix,
instrument (xvii) period refers to xx)
(xviii)
-------------- --------------- --------------- --------------- ------------------------------ -----------------------
N/A Nominal Delta
-------------- --------------- --------------- --------------- ------------------------------ ------------ ---------
Total (A+B+C)
--------------------------------------------------------------------------------------------------------------------------
Number of voting rights Percentage of voting rights
----------------------------------------------------------------- -------------------------------------------------------
7,284,981 3.03%
----------------------------------------------------------------- -------------------------------------------------------
9. Chain of controlled undertakings through which the
voting rights and/or the
financial instruments are effectively held, if applicable:
(xxi)
--------------------------------------------------------------------------------------------------------------------------
N/A
Proxy Voting:
--------------------------------------------------------------------------------------------------------------------------
10. Name of the proxy holder: N/A
----------------------------------------------------------------------- -------------------------------------------------
11. Number of voting rights proxy
holder will cease
to hold:
----------------------------------------------------------------------- -------------------------------------------------
12. Date on which proxy holder will
cease to hold
voting rights:
----------------------------------------------------------------------- -------------------------------------------------
13. Additional information:
---------------------------------------------------- --------------------------------------------------------------------
14. Contact name: Vanguard Health Care Fund
c/o The Vanguard Group, Inc.
Vanguard_Fund_Compliance@Vanguard.com
---------------------------------------------------- --------------------------------------------------------------------
15. Contact telephone number: +001 (610) 669-8989
---------------------------------------------------- --------------------------------------------------------------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
HOLUVOBRBVAWURR
(END) Dow Jones Newswires
August 25, 2017 03:41 ET (07:41 GMT)
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Apr 2024 to May 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From May 2023 to May 2024
